Intr3pid
DIS Veteran
- Joined
- Mar 2, 2018
So, J&J is actually conducting a two-dose trial in parallel. Known as ENSEMBLE 2, it was launched in November and would involve up to 30,000 participants.
https://www.jnj.com/johnson-johnson...nterim-analysis-of-its-phase-3-ensemble-trial
It's not clear whether these are new participants or the single-dose participants being given a second dose. The single-dose trial was launched in September two months before the double-dose launch. It means we might get the double-dose results in March - and if the company just began a reformulated vaccine study, the results from that study by early summer.
More data at hand from the single-dose trial results:
https://www.jnj.com/johnson-johnson...nterim-analysis-of-its-phase-3-ensemble-trial
It looks like the South African cases comprised about 15% of the total. I don't know if it's coincidental, but they did report 15% incidence of the severe cases overall.
https://www.jnj.com/johnson-johnson...nterim-analysis-of-its-phase-3-ensemble-trial
It's not clear whether these are new participants or the single-dose participants being given a second dose. The single-dose trial was launched in September two months before the double-dose launch. It means we might get the double-dose results in March - and if the company just began a reformulated vaccine study, the results from that study by early summer.
More data at hand from the single-dose trial results:
https://www.jnj.com/johnson-johnson...nterim-analysis-of-its-phase-3-ensemble-trial
It looks like the South African cases comprised about 15% of the total. I don't know if it's coincidental, but they did report 15% incidence of the severe cases overall.